SolutionSolution
Schedule H (Prescription Required)Glaucoma Drops & Pressure ReducersCode: 2025

Bimatoprost 0.03% w/v + Timolol 0.5% w/v Ophthalmic Solution

Generic Formulation:Bimatoprost 0.03% w/v and Timolol 0.5% w/v Ophthalmic Solution
Pack Size:5ml Drops
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹159.38
Brand Estimate*
₹580
Estimated Savings:₹420.62 (73% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Bimatoprost (0.01%, 0.03% w/v, alone or with Timolol 0.5%) is a synthetic prostamide (cyclopentane amide) ocular hypotensive agent on the WHO Model List of Essential Medicines. It structurally mimics endogenous prostamides, binding to unique prostamide receptors to simultaneously increase both trabecular meshwork and uveoscleral aqueous humor outflow, achieving powerful intraocular pressure reduction. Indicated for the reduction of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 2025.Report inaccuracy

Usage Guidelines

Instill one drop into the affected eye(s) once daily in the evening. Wipe away excess solution from the eyelid margins to prevent unwanted periorbital hyperpigmentation and periocular hair growth. Remove contact lenses before use.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Conjunctival hyperemia, ocular pruritus, iris hyperpigmentation (permanent), eyelash growth, periorbital fat atrophy (deepening of eyelid sulcus), dry eyes. Rare/Severe: Cystoid macular edema, iritis, and exacerbation of asthma (if combined with timolol).

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

May cause permanent iris pigmentation changes and reversible periorbital fat loss (sunken eye appearance). Contraindicated in patients with active intraocular inflammation (uveitis/iritis). Discard bottle 4 weeks after opening.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.